Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
We determined that the enrollment of 3260 patients would be required to determine the primary outcome in at least 122 patients and provide a power of 90% to reject a hazard ratio of at least 1.80 at the 0.05 level of significance
Start slow during titration The first several weeks of GLP-1 treatment involve dose titration a gradual increase in medication strength designed to minimize side effects
When to suspect euglycemic DKA Any patient with Type 1 or 2 diabetes taking SGLT-2 inhibitors who presents with nausea, vomiting, SOB or malaise or is found to have a metabolic acidosis should have blood drawn for serum ketones
Who Is Eligible for Semaglutide
We recommend a simple framework to ensure your body has the resources it needs while on a GLP-1 program
